Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) fell 7.9% on Wednesday . The stock traded as low as $0.50 and last traded at $0.51. 187,369 shares traded hands during trading, a decline of 87% from the average session volume of 1,417,318 shares. The stock had previously closed at $0.55.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday, March 27th.
Read Our Latest Analysis on Kiora Pharmaceuticals
Kiora Pharmaceuticals Stock Performance
Institutional Trading of Kiora Pharmaceuticals
Several large investors have recently added to or reduced their stakes in KPRX. Boothbay Fund Management LLC purchased a new stake in Kiora Pharmaceuticals during the 4th quarter valued at about $40,000. Dimensional Fund Advisors LP acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $41,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals in the 4th quarter valued at about $49,000. Renaissance Technologies LLC acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $58,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $70,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Read More
- Five stocks we like better than Kiora Pharmaceuticals
- What Are Dividend Contenders? Investing in Dividend Contenders
- Comprehensive Analysis of PayPal Stock
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- What is the Euro STOXX 50 Index?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.